On January 26, 2021 Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, reported the closing of its previously announced registered direct offering of 25,925,925 shares of common stock at a purchase price of $1.35 per share, priced at-the-market under Nasdaq rules, resulting in net proceeds of $32.6 million, after deducting placement agents’ fees but before expenses payable by the Company (Press release, Celsion, JAN 26, 2021, View Source [SID1234574346]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A.G.P./Alliance Global Partners acted as the lead placement agent for the offering.

Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as co-placement agent for the offering.

Celsion intends to use the net proceeds for general corporate purposes, including research and development activities, capital expenditures and working capital.

This offering was made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-227236), previously filed with the Securities and Exchange Commission (the "SEC") on September 7, 2018 and declared effective on October 12, 2018, and an additional registration statement pursuant to Rule 462(b) (File No. 333-252320) under the Securities Act of 1933, as amended. The offering of the shares of common stock were made by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering are filed with the SEC and are available on the SEC’s website at View Source or by contacting A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On January 26, 2021 Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the "Company")reported that successfully completed the placement of the subordinated mandatory convertible notes, which the Company’s Executive Board resolved to issue with the approval of the Supervisory Board on January 7, 2021 (Press release, Epigenomics, JAN 26, 2021, View Source [SID1234574338]). In total, the mandatory convertible bond in the nominal amount of EUR 5,500,000.00 was fully placed. The offering was significantly oversubscribed. The mandatory convertible bond consists of 500,000 bonds, which are convertible into 5,000,000 registered shares of the Company. The gross proceeds from the issuance of the mandatory convertible bond amount to EUR 5.5 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On January 26, 2021 Bristol Myers Squibb (NYSE:BMY) reported a charitable donation totaling JPY 5.5 billion, or approximately USD 53 million, to Kyoto University, a leading state-run research university in Japan (Press release, Bristol-Myers Squibb, JAN 26, 2021, View Source;to-Support-Its-Cancer-Research/default.aspx [SID1234574337]). The donation, to be paid by Bristol-Myers Squibb K.K., will support immuno-oncology research being led by Tasuku Honjo, a Nobel laureate and Distinguished Professor of the university.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The funds will be used to finance the construction of the main building of the Center for Cancer Immunotherapy and Immunobiology, a newly established immuno-oncology research institute headed by Professor Honjo. Construction of the building, which will be named the Bristol Myers Squibb Building at the Center for Cancer Immunotherapy and Immunobiology, is scheduled to begin in 2021.

The Center for Cancer Immunotherapy and Immunobiology was established in April 2020 as a research institute within Kyoto University’s Graduate School of Medicine, and is the first ever Japanese academic institute dedicated solely to immuno-oncology research. The center serves as a hub for scholars from Japan and overseas pursuing scientific advancement of immuno-oncology in search of next-generation cancer treatments.

Professor Honjo, the founding director of the center, is a Distinguished Professor of the Kyoto University Institute for Advanced Study. In 2018 he won the Nobel Prize in Physiology or Medicine for his discovery in 1992 of the immune cell protein PD-1, which led to new therapies that have proven effective in the fight against cancer.

The Bristol Myers Squibb Building at the Center for Cancer Immunotherapy and Immunobiology will be located inside the university’s downtown Kyoto campus. Based on a design by Tadao Ando Architect & Associates, it will be a five-story complex with one underground floor with a total floor area of approximately 9,500 square meters, functioning as the main facility for the center in allowing researchers, faculty members and corporations to support early-career principal investigators and enhanced industry-academia collaboration.

Professor Tasuku Honjo said, "I have been working with researchers at BMS for a very long time on the development of Opdivo and other medicines. The donation we are receiving from BMS will help us build the Bristol Myers Squibb Building at the Center for Cancer Immunotherapy and Immunobiology in the Kyoto University Graduate School of Medicine. It is a major milestone in industry-academia collaboration that is based on mutual trust. The collaboration between academia and industry in drug development is more important than ever and it is a great pleasure to see the decades-long friendship between BMS and Kyoto University come to fruition in this way, lighting a beacon of hope for future cancer researchers."

Jean-Christophe Barland, President and CEO of Bristol-Myers Squibb K.K., said, "I am excited about the opportunity to support the world’s leading immuno-oncology research being undertaken at Kyoto University under Professor Honjo’s leadership. BMS is dedicated to the fight against cancer in Japan and around the world. For BMS who has been a pioneer in immuno-oncology, this financial contribution is a testament to our focus on, and commitment to, the discovery, development and delivery of innovative cancer treatments."

On January 26, 2021 Notable Labs, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, reported that it is hosting a live webinar on February 9th to unveil their integrative data platform (Press release, Notable Labs, JAN 26, 2021, View Source [SID1234574366]). The Notable data scientists will share an in-depth discussion on how data generated from the functional and multi-omic drug sensitivity screen for Acute Myeloid Leukemia (AML) can be harnessed for biomarker discovery, improved drug development and complement patient mutational data for more precise treatment strategies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This webinar will highlight the integration of three technologies: a flow-cytometry drug sensitivity screen, DNA-Seq, and RNA-Seq," said CEO Laurie Heilmann. "By augmenting a stand-alone drug sensitivity screen with multi-omic data, Notable Labs is amassing a continually-growing dataset that ultimately will provide utility for drug development and patient care in AML and other Hematologic oncology indications."

The webinar will cover how this dataset, containing samples with matched drug sensitivity, gene expression, and variant data, enables researchers to look at the relationships between different data types. The data analysis can then be used to discover biomarkers, look at patient population stratification, and gain a deeper understanding of how drug sensitivity is influenced by genetics and gene expression. Advanced registration is required. Please see [link] for complete registration information.

On January 19, 2021 Turret Capital Management, a global investment and venture building firm focused on the healthcare industry, reported that it has signed a Definitive License Agreement with Genexine, inc.(KOSDAQ 095700), a South Korea-based Biotechnology company. Under the terms of the agreement, Turret Capital has obtained global rights for selective indications to GX-P1. GX-P1 is a Phase I ready novel immunosuppressant agent that reduces the immune response by binding to PD-1 on activated T cells and thus inhibiting T cell activation; a mechanism that is opposite to that of an anti-PD-L1 immune checkpoint inhibitor typically used to treat cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The compound will be housed and developed within Egret Therapeutics, a subsidiary of Turret Capital, and will target clinical areas of unmet need in the area of acute subarachnoid hemorrhage. Daniel Chai, M.D., Executive Chairman of Egret Therapeutics and Managing Partner of Turret Capital, stated, "Our firm strives to develop and market the most compelling and innovative technologies to address large market opportunities in healthcare. We are excited to partner with Genexine on this Phase I ready asset and leverage our scientific and clinical expertise in Neurological diseases to better help patients that suffer from the debilitative and life-threatening conditions of stroke."

Sung Yung-Chul, Ph.D., Founder and CEO of Genexine stated, "We are excited about working with the team at Egret Therapeutics and leadership at Turret Capital. Through our partnership, we believe we can achieve maximal value for innovative products that have been developed within Genexine."

Under the terms of the agreement, Genexine will receive 5% of underlying Egret Therapeutics outstanding shares and be eligible to receive development and commercial milestones payments of up to $200 million USD.On